Dual Inhibition With Bezuclastinib/Sunitinib Aims to Fill an

Combination therapy targeting multiple exons where mutations commonly develop in gastrointestinal stromal tumor may represent a promising treatment approach to increase efficacy when patients develop resistance to therapies such as imatinib.

Related Keywords

United Kingdom , Houston , Texas , United States , London , City Of , American , Neeta Somaiah , Robin Jones , Department Of Sarcoma Medical Oncology , American Society Of Clinical Oncology Annual Meeting , University Of Texas Md Anderson Cancer Center , Division Of Cancer Medicine , Sarcoma Medical Oncology , Cancer Medicine , Cancer Center , Sarcoma Unit , Royal Marsden , Data Sets , Peak Part , Clinical Oncology Annual Meeting , Gastrointestinal Stromal Tumor , Gist , Imatinib ,